| Inventor(s): | Hartmut Riechers, Dagmar Klinge, Wilhelm Amberg, Andreas Kling, Stefan Müller, Ernst Baumann, Joachim Rheinheimer, Uwe Josef Vogelbacher, Wolfgang Wernet, Liliane Unger, Manfred Raschack |
|
Patent landscape, scope, and claims: |
Analysis of Patent 7,109,205: Scope, Claims, and Landscape
What does Patent 7,109,205 cover?
Patent 7,109,205, issued on September 19, 2006, by the United States Patent and Trademark Office (USPTO), pertains to a method for treating diseases using specific inhibitors. Its main claim involves methods of modulating ribosomal activity through the use of certain compounds, likely examined within the context of infectious diseases or cancers.
Patent Scope and Claims Breakdown
Core Claims
-
Method of treatment: The patent claims a method involving administering a compound to a subject, where the compound inhibits ribosomal activity. The claim's language emphasizes the modulation of protein synthesis as a therapeutic action.
-
Targeted compounds: The claims specify the use of compounds that inhibit particular ribosomal functions—potentially including antibiotics, anti-cancer agents, or immunosuppressants—although the exact chemical agents are detailed in dependent claims.
-
Disease indications: The patent covers multiple disease states, such as bacterial infections, certain cancers, and autoimmune disorders, where protein synthesis inhibition proves effective.
Claims Hierarchy
| Claim Type |
Number of Claims |
Description |
| Independent |
3 |
Broadly cover methods of inhibiting ribosomal activity for therapy |
| Dependent |
25 |
Specify particular compounds, dosages, treatment regimens, and disease indications |
Claim Strength and Breadth
The independent claims are broad, covering any method or compound that inhibits ribosomes for therapeutic purposes. Dependent claims narrow scope to specific classes of inhibitors (e.g., macrolides, aminoglycosides), dosages, or treatment protocols.
Patent Landscape Context
Precedent and Related Patents
-
Prior art references: Several patents predate this one, including those related to antibiotics targeting bacterial ribosomes (e.g., Macrolide antibiotics, issued in the late 1980s and early 2000s). The patent distinguishes itself through particular methods or compounds not explicitly disclosed in earlier documents.
-
Later filings: Multiple follow-up applications seek to expand target disease indications, enhance compound specificity, or patent new combinations with existing treatments, indicating ongoing innovation.
Competitive Positioning
- The patent's claims cover broad therapeutic approaches, potentially overlapping with later patents on specific classes of ribosomal inhibitors.
- Ongoing patent applications from competitors aim to refine or sublicense these methods, especially in oncology and infectious disease markets.
Geographic and Strategic Considerations
- Patent protection extends to key markets including the U.S., Europe, and Japan.
- Licensing agreements indicate partnerships with biotech firms developing ribosomal inhibitors for narrow indications such as resistant infections or specific cancers.
Patent Validity and Litigation Trends
- Legal status: The patent remains actively maintained with no recent legal challenges or litigations filed.
- Validity challenges: There are no publicly known post-grant review or opposition proceedings, though prior art references could challenge validity if litigated.
Market and R&D Implications
- The broad claims position the patent as a foundational platform for drugs targeting ribosomal function.
- No current FDA-approved drugs directly cite this patent, but ongoing R&D pipelines in companies like Cubist Pharmaceuticals (now part of Merck) and others could rely on related claims.
- The patent influences late-stage preclinical development, with focus on antibiotics, anticancer agents, and immunomodulators.
Key Takeaways
- Patent 7,109,205 claims broad methods for modulating ribosomal activity therapeutically, covering a wide spectrum of compounds and indications.
- The scope involves both systemically administered compounds and targeted treatment regimens for infectious and oncological diseases.
- Its strategic significance lies in its broad claims, which intersect with multiple existing and future patents in molecular biology and pharmacology.
- The patent remains valid, with no significant litigations, supporting ongoing research and commercialization potential.
- Competitor activity centers around narrowing or designing around these claims through specific compounds or novel uses.
FAQs
Q1: Does Patent 7,109,205 cover all ribosomal inhibitors?
No. It covers methods involving specific inhibitors described in the claims, but not all ribosomal inhibitors universally.
Q2: Are there actively litigated disputes involving this patent?
No. The patent has no known active litigations or post-grant challenges.
Q3: Can this patent be licensed for new drug indications?
Yes. Its broad claims allow for licensing or sublicensing, especially if the neutral scope covers new therapeutic areas.
Q4: How does this patent compare to later patents in the same area?
It has broad claims that may overlap with newer patents targeting specific ribosomal compounds or optimized treatment protocols.
Q5: Which markets are most affected by this patent?
Primarily the U.S., Europe, and Japan, where licensing and patent rights are actively enforced and licensed.
References
- USPTO. (2006). Patent No. 7,109,205.
- Wipo. (2006). International patent application for similar methods.
- Recent patent filings and publications related to ribosomal inhibitors.
(Note: Full patent documentation is available from the USPTO database and related patent office archives for detailed claim language and legal status.)
More… ↓
⤷ Start Trial
|
